Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Minot Light Capital Partners Tom Wetherald and Eddie Reilly | “Rockwell Medical is a company we have followed since the fund's inception and have had many conversations with management during this period of time. The reason we have kept a close eye on the company is due to the generally recurring nature of the core business in hemodialysis bicarbonate concentrates, where it essentially has a duopoly in the US. In addition, we have been impressed by how CEO Dr. Mark Strobeck has guided the company through several challenging periods since joining in 2022, emerging from each in a stronger position, while steadily expanding margins. These efforts have brought Rockwell to the point where it should now be generating positive cash flow. We have been slowly increasing our position in Rockwell this year, as the company has been executing well while the stock has been falling. Shares of Rockwell had fallen under $1.00/share and it seemed inevitable that the company would have to initiate a reverse stock split to avoid being de-listed. On June 29, 2026, Rockwell announced a reverse split that would be executed on July 1, 2026. The stock fell about 24% from a high of $6.80 on 6/26 to a low of $5.19 on 7/1 (post-split prices). We have been meaningfully increasing our position in RMTI during the past few weeks to take advantage of what we believe is a classic inefficiency around the announcement of a reverse-stock split. If Rockwell continues to execute according to plan, it could take revenues from the current run-rate of around $70M to $100M by 2030 and generate $5-$10M of free cash flow. The company is now trading around $5.50/share with 4.6M fully diluted shares outstanding with $15M of net cash on its balance sheet. This equates to a market cap of $25M, an enterprise value of only $10M, and an EV/Sales ratio of 0.14x. Net cash and investments per share total approximately $3.50.” | NEUTRAL | Q2 2026 Jul 21, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
